|
|
Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Enalapril#Adult Indications and Dosage]] |
| {{Enalapril}}
| |
| {{CMG}}; {{AE}} {{AM}}
| |
| | |
| ==INDICATIONS AND USAGE==
| |
| | |
| ====Hypertension====
| |
| | |
| VASOTEC is indicated for the treatment of [[hypertension]].
| |
| | |
| VASOTEC is effective alone or in combination with other [[antihypertensive agents]], especially thiazide-type diuretics. The blood pressure lowering effects of VASOTEC and [[thiazides]] are approximately additive.
| |
| | |
| ====Heart Failure====
| |
| | |
| VASOTEC is indicated for the treatment of symptomatic [[congestive heart failure]], usually in combination with diuretics and digitalis. In these patients VASOTEC improves symptoms, increases survival, and decreases the frequency of hospitalization.
| |
| | |
| ====Asymptomatic Left Ventricular Dysfunction====
| |
| | |
| In clinically stable asymptomatic patients with [[left ventricular dysfunction]] ([[ejection fraction]] ≤35 percent), VASOTEC decreases the rate of development of overt [[heart failure]] and decreases the incidence of hospitalization for heart failure.
| |
| In using VASOTEC consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused [[agranulocytosis]], particularly in patients with [[renal impairment]] or [[collagen vascular disease]], and that available data are insufficient to show that VASOTEC does not have a similar risk.
| |
| | |
| In considering use of VASOTEC, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving [[ACE inhibitors]] have been reported to have a higher incidence of angioedema compared to non-blacks.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VASOTEC (ENALAPRIL MALEATE) TABLET VASOTEC (ENALAPRIL MALEATE) TABLET [BTA PHARMACEUTICALS INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d181743-a0fc-4d17-953d-b17a936f9ecc | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |